Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Georgetown University · Georgetown University Medical Center · +3 more institutions
Indexed inpubmed
Abstract
Objective
To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD.
Design
Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications.
Citation impact
963
total citations
- FWCI
- 37.14
- Percentile
- 100%
- References
- 29
Citations per year
Authors
10Topics & keywords
Topics
Keywords
- Medicine
- Rofecoxib
- Internal medicine
- Placebo
- Clinical Dementia Rating
- Donepezil
- Dementia
- Alzheimer's disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.